Search Results 791-800 of 18073 for Alopecia

  1. A Study of SC‑004 in Subjects With Advanced Solid Tumors - Mayo Clinic

    Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration. Satisfactory laboratory ...

  2. A Study of DCC-2618 vs. Sunitinib in Advanced GIST Patients after Treatment with Imatinib - Mayo Clinic

    Resolution of all toxicities from prior therapy to ≤ Grade 1 (or patient baseline) within 1 week prior to the first dose of study drug (excluding alopecia ...

  3. A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1) - Mayo Clinic

    ... alopecia or fatigue [up to Grade 2 allowed]) from AEs resulting from prior immunotherapies. Patients who have autoimmune AEs controlled by replacement ...

  4. Betamethasone and calcipotriene (topical application route) - Mayo Clinic

    Betamethasone is a corticosteroid (cortisone-like medicine or steroid). It helps relieve redness, pain, itching, swelling, or other discomfort caused by certain ...

  5. Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma - Mayo Clinic

    Note: Patients with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study. Note: If patients ...

  6. Dandruff - Symptoms and causes - Mayo Clinic

    Skin flakes on your scalp, hair, eyebrows or shoulders. Itchy scalp. Scaly, crusty scalp in infants. This also is called cradle cap. Dandruff may get worse when ...

  7. JavaScript is disabled. In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.

  8. https://www.mayoclinic.org/chinese_patient_consumer_video.xml

  9. Mayo Clinic

    YouTube - MSP International Airport - Mayo Clinic Patient Video Guide - Minnesota · Fuel groundbreaking medical research! · About Mayo Clinic · Medical ...

  10. Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer - Mayo Clinic

    Participation eligibility · Anemia; · Alopecia; · Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of occurrence, and must ...